Oral etoposide for refractory and relapsed neuroblastoma
Antineoplastic Agents, Phytogenic
Bone Marrow Neoplasms
Neoplasm Recurrence, Local
Given the absence of toxicity to major organs, the minimal myelosuppression or immunosuppression, and the antineoplastic activity in patients with low tumor burdens after high-dose chemotherapy, limited use of low-dose oral etoposide should be considered for inclusion in postinduction consolidative treatment programs aimed at eradicating minimal residual disease.